Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT trial of sparsentan in immunoglobulin A nephropathy
2023-505495-30-00Phase 3Completed
- Sponsor
- Travere Therapeutics
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of sparsentan in IgA nephropathy (IgAN) (4 arms), sponsored by Travere Therapeutics. Primary endpoints: Change from baseline in urine protein/creatinine ratio at Week 36, Safety summary and 11 more. Started Feb 2019; status: completed.
02
Drugs
sparsentan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2023-505495-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505495-30-00.